advertisement
Abstract #84092 Published in IGR 21-1
Economic Burden of Non-Infectious Inflammatory Eye Disease (NIIED) in a Commercially-Insured Population in the United States
Albini TA; Rice JB; White AG; Johnson M; Reiff J; Lima AF; Bartels-Peculis L; Ciepielewska G; Nelson WWOcular Immunology and Inflammation 2020; 28: 164-174
: To assess the economic burden of non-infectious inflammatory eyedisease (NIIED) in a commercially-insured population in the United States: Adult patients with a NIIED diagnosis between 2006 and 2015 were selected from a de-identified, privately insured claims database and were matched 1:1 to a non-NIIED control. Ophthalmologic complications, direct healthcare resource use and costs, and indirect work loss (from the payer perspective) were calculated for a 12-month period and compared across the 2 cohorts.: Among the 14 876 matched pairs, NIIED patients were significantly more likely than controls to experience ocular complications, including glaucoma and cataracts ( < 0.001). NIIED patients had significantly higher healthcare resource utilization and costs compared with matched controls (relative difference 40%, < 0.001). NIIED patients missed 12.2 days of work ($2925 annual work-loss costs), 46% more than non-NIIED patients ( < 0.001).: NIIED imposes a significant clinical and economic burden, suggesting an unmet need for expanded access to alternative treatment options.
Bascom Palmer Eye Institute, University of Miami, Miami, Florida, USA.
Full articleClassification:
14 Costing studies; pharmacoeconomics
